▎WuXiEdited by the Kant Content Team

Drawing on Anti-Aging Mechanisms, Novartis Secures Over $500 Million R&D Collaboration

BioAge Labs Announces Multi-Year Research Collaboration with NovartisThis collaboration aims to discover and validate multiple novel therapeutic drug targets by studying the biological mechanisms underlying age-related diseases and the mechanisms mediating the health benefits of exercise.

This collaboration will combine BioAge's proprietary human longevity dataset with Novartis' expertise in the field of exercise biology.BioAge's proprietary discovery platform is based on longitudinal exclusive follow-ups of human aging cohorts, with follow-up durations of up to 50 years, including detailed health records and functional measurements.Using machine learning and advanced analytical methods to analyze these rich datasets,BioAge can discover the decisive factors of healthy lifespan, driving the discovery and development of therapeutic drugs.

Under the terms of the agreement, BioAge will receive an upfront payment and research funding totaling $20 million, with the potential to obtain up to $530 million in long-term research, development, and commercialization milestone payments in the future. Both Novartis and BioAge have the right to advance new targets discovered through the collaboration and are eligible for corresponding milestone payments.

Novo Nordisk Reaches Nearly $200 Million Collaboration to Develop Bispecific Molecules

Photys Therapeutics today announced a multi-year collaboration and licensing agreement with Novo Nordisk to develop innovative therapeutic drugs targeting cardiometabolic disease targets. This collaboration combines Novo Nordisk's deep expertise in the field of cardiometabolic diseases with Photys' proprietary phosphorylation-induced chimeric small molecules (PHICS) Technology.The PHICS technology platform can generate bispecific molecules, one end of which binds to a protein kinase and the other end binds to a target protein. By inducing the kinase to move closer to the target protein, the target protein becomes phosphorylated, thereby altering its biological function.

Under the terms of the agreement, Photys will be eligible to receive upfront, development, and commercialization milestone payments of up to $186 million, along with research and development funding support. Under the proposed R&D plan, Novo Nordisk and Photys will collaborate to develop multiple PHICS molecules targeting cardiometabolic disease targets. Photys will be responsible for advancing the preclinical development of PHICS molecules, after which Novo Nordisk will take over to advance these molecules through IND filing and clinical development.

Photys Therapeutics Focuses on Utilizing Its Proprietary PHICS Technology to Induce Kinase Proximity to Target Proteins, Causing Phosphorylation of the Target Protein to Achieve the Desired Biological Function Change. This Technology Can Selectively Recruit Kinases in Specific Tissues or Cellular Regions, Enabling Precise Regulation.

▲To learn more about the application of cutting-edge technologies in the biopharmaceuticals industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.